GlassScriptPhysician profile
Jorge A Gonzalez
NPI 1073567392
$18,771.17
in general payments reported to CMS, 2019-2025
64 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,344 · 2020: $2,401 · 2021: $2,392 · 2022: $3,276 · 2023: $3,537 · 2024: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.72 |
| Education | $112.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,895.65 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $1,230.56 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $1,203.64 | 2019-2024 | Austedo Xr, Ajovy |
| Sk Life Science, INC. | $1,144.03 | 2020-2024 | Xcopri |
| Ucb, INC. | $1,024.44 | 2019-2024 | Briviact, Fintepla, Nayzilam |
| Lilly USA, LLC | $885.30 | 2019-2023 | Reyvow, Emgality |
| Medtronic USA, INC. | $867.18 | 2019 | |
| Abbvie INC. | $769.25 | 2021-2024 | |
| Amgen INC. | $748.95 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $634.99 | 2019-2024 | Qelbree |
| Lundbeck LLC | $622.61 | 2019-2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $538.65 | 2019-2024 | Ultomiris |
| Biogen, INC. | $537.30 | 2019-2022 | |
| Eisai INC. | $506.33 | 2019-2024 | |
| Kyowa Kirin, INC. | $427.73 | 2021-2024 | Nourianz |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.